NEW YORK — Theralink Technologies said on Monday that it is working with George Mason University and the Rutgers Cancer Institute of New Jersey to commercialize an assay that can guide treatment of HER2 positive breast cancer patients.
The institutes recently received the US Army's Breast Cancer Research Program Breakthrough Award, worth $1.3 million, to clinically validate a test developed at George Mason that measures HER2 activation (phosphorylation) in a breast cancer biopsy to help determine if a patient will respond to treatment.